### Supplementary Table 4. Correlates of Banff Borderline TCMR versus No TCMR excluding recipients who developed dnDSA

|                              | Univariate |                     | Multivariate |                     |
|------------------------------|------------|---------------------|--------------|---------------------|
|                              | Hazard Ratio | p value | Hazard Ratio | p value |
| First Transplant versus two or more | 1.35 (0.50-3.67) | 0.5354 |                     |                     |
| Recipient Age (years)        | 0.98 (0.97-0.98) | <0.0001 | 0.98 (0.96-0.98) | <0.0001 |
| Donor Age (years)            | 0.99 (0.98-1.00) | 0.4794 |                     |                     |
| Living Donor                 | 0.87 (0.59-1.26) | 0.4477 |                     |                     |
| Ethnicity (Caucasian vs. other) | 0.83 (0.57-1.22) | 0.3565 |                     |                     |
| Cold Ischemic Time (hours)   | 1.03 (0.99-1.06) | 0.1404 |                     |                     |
| Delayed Graft Function       | 1.32 (0.44-1.30) | 0.3307 |                     |                     |
| Induction Therapy versus none | 1.62 (1.12-2.37) | 0.0108 |                     |                     |
| Tacrolimus versus Cyclosporin | 0.40 (0.22-0.72) | 0.0025 | 0.36 (0.19-0.66) | 0.0011 |
| Alloimmune Risk Category (Low, Intermediate, High) | | | | |
| Intermediate vs Low          | 2.18 (1.29-3.69) | 0.0038 | 2.81 (1.63-4.84) | 0.0002 |
| High vs Low                  | 1.77 (1.03-3.04) | 0.0403 | 2.34 (1.34-4.10) | 0.0030 |